Clinical Trial Search

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants

Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day

Primary: Composite Success Assessment (CEA) and Patient Self Assessment(PSA). — 32; 48; 33; 46 participants

Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001

Primary: Composite Success — 40; 14; 39; 12 participants — p=<0.001

Primary: Mean Change in Pain in the Treated Human Arm (Not Placebo) From Baseline Determined by Measures (17) Taken Over 24 Hours — 0.13; -0.19; -0.46; -0.31 units on a scale

Primary: Level of Pain — .39; .19; .14; .56 units on a scale

Primary: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) — 13.3; 20.5…

Primary: Change From Baseline (V2) in Frequency and Severity of Dry Eye Symptoms (SANDE) Questionnaire Scores at Day 28±4 (End of Treatment) — -11.9; -16.6; -25.0; -26.5 mm

Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…

Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001

Primary: Composite Success — 16; 10; 10; 2 participants — p=<0.001

Primary: Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point…

Primary: Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale — 0.908 Kendall's W